CLLS - Cellectis S.A.
| Previous Close | 16.84 |
| Open | 17.01 |
| Bid | 16.00 x 800 |
| Ask | 25.00 x 800 |
| Day's Range | 16.83 - 17.36 |
| 52 Week Range | 15.34 - 38.85 |
| Volume | 144,267 |
| Avg. Volume | 126,868 |
| Market Cap | 730.197M |
| Beta (3Y Monthly) | 1.68 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.11 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 43.90 |
- GlobeNewswire•17 days ago
Consolidated Research: 2019 Summary Expectations for Oceaneering International, Southwest Gas, WellCare Health Plans, Barnes & Noble, Cellectis S.A, and Payment Data — Fundamental Analysis, Key Performance Indications
NEW YORK, Feb. 07, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Business Wire•2 months ago
Cellectis Appoints William Monteith as Senior Vice President U.S. Manufacturing
Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART), today announced the appointment of William (Bill) Monteith to the role of Senior Vice President U.S. Manufacturing. This appointment follows Cellectis’ plan to establish commercial manufacturing capabilities in the U.S., which will be Bill Monteith’s responsibility, notably through the deployment of a proprietary state-of-the-art gene-edited cell manufacturing plant for clinical and commercial supplies of our current immuno-oncology UCART product candidates. Bill Monteith joins Cellectis from Hitachi Chemical Advanced Therapeutics Solutions, where he was the Chief Operating Officer and Site General Manager for three manufacturing facilities.
- Business Wire•3 months ago
Cellectis Reports Financial Results for 3rd Quarter and First Nine Months 2018
NEW YORK-- -- UCART123 in Phase 1 clinical trial for AML and BPDCN patients; UCART22 Phase 1 study protocol approved by FDA for B-ALL patients; UCART19 ASH abstract by partner Servier shows continued progress of first clinical allogeneic CAR T-cell program for ALL patients; UCARTCS1 clinical trial expected to start in 2019 for Multiple Myeloma patients; Cash 1 position of $476M as of September 30, ...
- Business Wire•5 months ago
CAR-T Pioneer Dr. Stephan A. Grupp to Join Cellectis Clinical Advisory Board
Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART), today announced that Stephan A. Grupp, MD, Ph.D., a leading pediatric oncologist at Children's Hospital of Philadelphia and Chief of the Section of Cellular Therapy and Transplant at the Children's Hospital of Philadelphia (CHOP) joined the Company’s Clinical Advisory Board (CAB). Dr. Grupp is a world-renowned pediatric oncologist and cancer researcher who initiated the first pediatric CAR T-cell trial for acute lymphoblastic leukemia at CHOP in 2012.
- Business Wire•5 months ago
Calyxt Appoints CEO, Jim Blome, Former President & CEO of Bayer CropScience LP
Calyxt, Inc. (CLXT) and Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) announced today the appointment of James A. Blome, former President and CEO of Bayer CropScience LP (North America), as Chief Executive Officer of Calyxt, effective October 1, 2018. Jim Blome will work closely with Calyxt’s Board of Directors to foster the development of the Company’s consumer-focused products, including the upcoming commercial launch of Calyxt’s first product, high-oleic soybean oil. Jim Blome is a high-impact, global leader with over 25 years of leadership experience in the agriculture industry, building teams and strategies with consumer-focused cultures to better meet consumer needs and maximize market share growth.
- Business Wire•7 months ago
Cellectis Appoints Stefan Scherer M.D., Ph.D., as Senior Vice President Clinical Development and Deputy Chief Medical Officer
Cellectis (ALCLS.PA) (CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today the appointment of Dr. Stefan Scherer, M.D., Ph.D., to the role of Senior Vice President Clinical Development and Deputy Chief Medical Officer. Dr. Scherer joins Cellectis from Novartis Pharmaceuticals Corporation, where he was the Head of Early Development, Strategy and Innovation for U.S. Oncology.
- Business Wire•7 months ago
Cellectis Reports Financial Results for 2nd Quarter and First Six Months 2018
NEW YORK-- -- FDA approves UCART123 protocol amendment to accelerate clinical development in AML patients FDA approves IND for UCART22 in B-ALL patients, which is the 3 rd allogeneic gene-edited CAR T-cell product candidate approved for clinical trials in the United States Allogene and Servier alliances to accelerate commercialization of allogeneic CAR T-Cell therapies $191M follow-on offering by Cellectis ...
- Business Wire•8 months ago
Cellectis S.A. Reports Results from Annual General Meeting Held on June 26, 2018
Regulatory News:
- Business Wire•8 months ago
Cellectis Publishes Novel Methods to Improve the Clinical Use of Chimeric Antigen Receptor T-Cell Therapy in Scientific Reports
Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART), today announced the publication of a study in Scientific Reports, a Nature Publishing Group journal, describing the development of the CubiCAR, an all-in-one Chimeric Antigen Receptor (CAR) architecture with an embedded multi-functional tag for purification, detection and elimination of CAR T-cells. This added versatility has the potential to streamline the manufacturing of CAR T-cells to allow their tracking and efficiently eliminate CAR T-cells in clinical settings. To identify an optimal CAR architecture, we selected 15 different CAR constructs and evaluated their ability to enable T-cell depletion and promote tumor eradication,” said Julien Valton, Ph.D., Innovation Team Leader of Cellectis.
- Simply Wall St.•9 months ago
Should Cellectis SA.’s (NASDAQ:CLLS) Recent Earnings Decline Worry You?
Assessing Cellectis SA.’s (NASDAQ:CLLS) past track record of performance is a useful exercise for investors. It allows us to understand whether the company has met or exceed expectations, which isRead More...
- Business Wire•9 months ago
FDA Grants Cellectis IND Approval for UCART22 in B-ALL
Cellectis (ALCLS.PA) (CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational New Drug (IND) application to initiate a Phase 1 clinical trial for UCART22, Cellectis’ second wholly controlled TALEN® gene-edited product candidate, for the treatment of B-cell acute lymphoblastic leukemia (B-ALL) in adult patients. UCART22 is the 3rd allogeneic, off-the-shelf, gene-edited CAR T-cell product candidate approved by the FDA for clinical trials in the U.S., following UCART19 (exclusively licensed to Servier and under joint development agreement between Servier and Allogene), and Cellectis’ UCART123.
- Business Wire•9 months ago
INSERTING and REPLACING: Approval of UCART123 Amendment in AML to Accelerate Clinical Development
Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today the approval of an amendment to the protocol for the Phase 1 clinical trial of Cellectis’ UCART123 product candidate in patients with acute myeloid leukemia (AML). Dose level 1 to be administered increases from 6.25x104 to 2.5x105 UCART123 cells per kilogram. Dose level -1 is now at 1.25x105.
- Business Wire•9 months ago
Cellectis: Approval of UCART123 Amendment in AML to Accelerate Clinical Development
Cellectis (ALCLS.PA) (CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today the approval of an amendment to the protocol for the Phase 1 clinical trial of Cellectis’ UCART123 product candidate in patients with acute myeloid leukemia (AML). The product’s safety and tolerability profile allowed Cellectis to increase the dose level.
- Business Wire•9 months ago
Cellectis S.A.: Calyxt Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
Regulatory News:
- Business Wire•9 months ago
Cellectis to Present Data at the 2018 ASGCT Annual Meeting
Regulatory News:
- ACCESSWIRE•10 months ago
Wired News - Atara Biotherapeutics Expands T-Cell Immunotherapy Collaboration with MSK to Develop Next-Generation CAR T Technologies
LONDON, UK / ACCESSWIRE / May 10, 2018 / If you want access to our free research report on Atara Biotherapeutics, Inc. (NASDAQ: ATRA) ("Atara"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ATRA as the Company's latest news hit the wire. On May 08, 2018, the Company announced that it has expanded its collaboration with Memorial Sloan Kettering Cancer Center ("MSK") to develop the next generation of genetically engineered chimeric antigen receptor T-cell (CAR T) immunotherapies. Active-Investors.com is currently working on the research report for Cellectis S.A. (NASDAQ: CLLS), which also belongs to the Healthcare sector as the Company Atara Biotherapeutics.
- Business Wire•10 months ago
Cellectis Files IND for UCART22 in Acute Lymphoblastic Leukemia (B-ALL)
Cellectis (ALCLS.PA) (CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today that the Company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) requesting approval to initiate a Phase 1 clinical trial for UCART22, Cellectis’ second wholly controlled TALEN® gene-edited product candidate, for the treatment of B-cell acute lymphoblastic leukemia (B-ALL) in adult patients.
- Business Wire•10 months ago
Harvard’s Wyss Institute Partners with Cellectis to Recode the Human Genome
Today the Wyss Institute for Biologically Inspired Engineering at Harvard University and Cellectis (ALCLS.PA) (CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS) a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced that they will collaborate to further advance the Wyss Institute’s efforts to recode the entire genome of cell lines derived from humans and other species, and to develop new tools and methods facilitating this goal. The cell lines would be engineered to resist debilitating viral infections while carrying out their normal functions, or even perform entirely new functions. Previously, the group of George Church, Core Faculty member at the Wyss Institute, Professor of Genetics at Harvard Medical School (HMS) and of Health Sciences and Technology at Harvard and the Massachusetts Institute of Technology (MIT), published on efforts to radically recode the bacterium E. coli’s genome.
